O-salicylylhydroxylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-salicylylhydroxylamine
• 英文别名: Ammonia salicylate；amino 2-hydroxybenzoate
• 化学式: C₇H₇NO₃
• 分子量: 153.137
• InChiKey: AIWXJLPLVDPBHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  水杨酸苯酯 在 sodium hydroxide 、 羟胺 作用下， 以 水 、 乙腈 为溶剂， 生成 O-salicylylhydroxylamine
  参考文献：
  名称：

  Khan, Mohammad Niyaz, Journal of the Chemical Society. Perkin transactions II, 1989, p. 199 - 208

  摘要：

  DOI：

文献信息

• FATTY ACID ACETYLATED SALICYLATES AND THEIR USES
  申请人：Milne Jill C.

  公开号：US20100041748A1

  公开（公告）日：2010-02-18

  The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

  本发明涉及脂肪酸乙酰水杨酸衍生物；包含有效量的脂肪酸乙酰水杨酸衍生物的组合物；以及用于治疗或预防炎症性疾病的方法，包括给药有效量的脂肪酸乙酰水杨酸衍生物。
• [EN] USE OF ESTROGEN RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE<br/>[FR] UTILISATION DE LIGANDS DE RECEPTEUR D'OESTROGENE POUR LE TRAITEMENT D'UNE MALADIE INTESTINALE INFLAMMATOIRE
  申请人：WYETH CORP

  公开号：WO2005039581A1

  公开（公告）日：2005-05-06

  The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.

  本发明涉及一种治疗炎症性肠病的方法，通过诊断一个人需要治疗炎症性肠病，并且通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的任一相互作用来给予调节NF-kB转录因子的配体的治疗有效量，且在很大程度上缺乏肌酸激酶刺激。在某些优选实施方式中，给药基本上没有子宫营养活性。
• [EN] PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR X DU FOIE A BASE DE DERIVES PYRROLE-,5-DIONE
  申请人：ASTRAZENECA AB

  公开号：WO2005005417A1

  公开（公告）日：2005-01-20

  The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及某些新颖化合物的公式（I），以及制备这些化合物的方法，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）方面的用途，以及在治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（失调脂质）以及与胰岛素抵抗、2型糖尿病和代谢综合征其他表现相关与否的临床病症方面的用途，以及它们的治疗用途的方法和含有它们的药物组合物。
• [EN] PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] DERIVES DE PYRROLE-2, 5-DITHIONE UTILISES COMME MODULATEURS DU RECEPTEUR X HEPATIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2005005416A1

  公开（公告）日：2005-01-20

  The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer´s disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一些新颖的化合物，其化学式为I，涉及制备这些化合物的方法，以及它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）方面的用途，以及用于治疗心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（失调脂质）是否与胰岛素抵抗有关、2型糖尿病和代谢综合征其他表现的临床病症，以及用于其治疗的方法和含有它们的药物组合物。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DOULEUR CHRONIQUE
  申请人：KANDULA MAHESH

  公开号：WO2013168011A1

  公开（公告）日：2013-11-14

  The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula 1 or formula II, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute pain (such as post-operative pain), palliative care to alleviate the severe., chronic, disabling pain of terminal conditions such as cancer, and degenerative conditions such as rheumatoid arthritis, non-malignant chronic pain, chemotherapy induced pain, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (R.l,S), cluster headache, depression, fibromyalgia and amyotrophic lateral sclerosis (A.LS).

  本发明涉及化合物的结构式(I)和结构式(II)或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括结构式1或结构式II化合物的有效量的药物组合物，以及用于治疗疾病中的慢性疼痛的方法，可以制备口服、颊内、直肠、局部、经皮、经粘膜、静脉、全身、糖浆或注射剂。这种组合物可以用于治疗急性疼痛（如术后疼痛）、缓解癌症等终末病症的严重、慢性、致残性疼痛的姑息护理，以及类风湿性关节炎、非恶性慢性疼痛、化疗引起的疼痛、肌肉骨骼疼痛、坐骨神经痛、神经根痛、偏头痛、神经性疼痛、带状疱疹后神经痛、神经痛、多发性硬化症、多发性硬化症、不宁腿综合征（RLS）、集束性头痛、抑郁症、纤维肌痛和肌萎缩侧索硬化症（ALS）的治疗。